The Administration Core C will identify and accomplish administrative tasks related to the POl and facilitate the communication and dissemination of research data among the investigators. POl leadership will use Core C to facilitate the oversight ofthe research projects and cores. Core C will ensure effective and rapid communication and cooperation among investigators, projects, and cores. This core will also assist in sharing our research data with other investigators both within and outside of Memorial Sloan-Kettering Cancer Center (MSK) with a special emphasis to link Dr. Pao and the RP3 team at Vanderbilt and Dr. Sordella at the Cold Spring Harbor Laboratory with all facets of the program project through the POl intranet wiki and videoconferencing. The Administration Core C will provide: (1) administrative services;regulatory and reporting services, including preparation of annual reports and renewals;(2) budget management;(3) publication management and oversight;(4) wiki/intranet website management;(5) videoconferencing for all POl activities;(6) scheduling of POl """"""""work-in-progress"""""""" conferences for the investigators and yearly face-toface presentations to our advisory committees;and (6) support of the oversight activities of the Executive and Scientific Advisory committees. The Administration Core C centralizes, expands, and improves the operational capabilities of all the individual research projects and cores, avoids duplication, and ensures optimum utilization of resources. The MSK Lung POl Administrator supported by this Core will meet twice monthly with the Principal Investigators and quarterly with the Executive Committee to assist them in monitoring the status of operations so that the research supported by the grant proceeds as rapidly and efficiently as possible. The MSK Lung POl Administrator, working with the Principal Investigators, will prepare and distribute a yeariy progress report for the Executive and the Internal and External Scientific Advisory Committees to assist in their annual review and oversight. The Administration Core C supports the Principal Investigators, Executive Committee, Scientific Advisory Committees, research projects and other cores;and provides services that are essential for the POl to function as an integrated research program to develop new targets for treatment for persons with lung cancers.

Public Health Relevance

Lung cancers are America's leading cancer killers, responsible for 158,000 deaths this year. This grant addresses the two most critical roadblocks to improving the care and curability of persons with these illnesses: (1) understanding how cancers spread (metastasis) and (2) the lack of highly effective medicines to prevent spread or to eradicate cancers that have spread from the lung. Core C is crifical to this effort.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA129243-07
Application #
8563899
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$119,583
Indirect Cost
$41,379
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Gao, Yijun; Chang, Matthew T; McKay, Daniel et al. (2018) Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov 8:648-661
Arbour, Kathryn C; Jordan, Emmett; Kim, Hyunjae Ryan et al. (2018) Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24:334-340
Gallant, Jean-Nicolas; Lovly, Christine M (2018) Established, emerging and elusive molecular targets in the treatment of lung cancer. J Pathol 244:565-577
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Yao, Zhan; Gao, Yijun; Su, Wenjing et al. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med :
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739
Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902
Ruscetti, Marcus; Leibold, Josef; Bott, Matthew J et al. (2018) NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362:1416-1422
Du, Zhenfang; Lovly, Christine M (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58

Showing the most recent 10 out of 188 publications